Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease

Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update

Read More
Castle Biosciences announces Medicare coverage for the DecisionDx-Melanoma test in cutaneous melanoma

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced Medicare coverage for the DecisionDx®-Melanoma test that predicts risk of metastatic disease and helps to guide use of sentinel lymph node biopsy (SLNB) in patients with cutaneous melanoma.

Read More
HealthQuest leads $26.5 million investment into BioIQ

HealthQuest led a $26.5 million investment into BioIQ, the leading platform for orchestrating health testing programs and biometric screening events across multiple vendors.  Additionally, BioIQ utilizes multi-channel communication tools for engaging and motivating participants.  HealthQuest was joined in this investment by Arboretum Ventures and select insiders. 

Read More
BioIQRandy Scott2018
HealthQuest participates in follow-on financing for Venus Concept

HealthQuest Capital, EW Healthcare partners and Madryn Asset Management invested an additional $7 million in Venus Concept concurrent with the completion of the acquisition of NeoGraft.  NeoGraft is an industry leader in the area of hair restoration technologies.  Venus Concept's industry first and only subscription-based business model, combined with its global reach in over 60 countries and 27 direct global offices, will create a significant opportunity to expand the overall combined businesses of both NeoGraft and Venus Concept.

Read More
Venus ConceptRandy Scott2018
HealthQuest leads $20 million investment into Springbuk

HealthQuest led a $20 million investment into Springbuk, the leading employer-facing health intelligence software.  HealthQuest was joined in this investment by Echo Health Ventures and Lewis & Clark Ventures.

Springbuk was founded in 2015 by Rod Reasen and Phil Daniels, co-founders of the Healthiest Employers awards program, with the mission to empower employers to lower their healthcare costs by harnessing their health data. Today, over 1,000 employers use Springbuk’s software to glean actionable insights to improve their population’s health.

Read More
SpringbukRandy Scott2018
Castle Biosciences Launches Next-Generation Sequencing Panel for Uveal Melanoma

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the launch of the DecisionDx®-UMSeq panel that uses next-generation sequencing (NGS) to identify somatic mutations in genes relevant to uveal melanoma (UM). The new test will complement Castle Biosciences’ standard-of-care DecisionDx®-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.

Read More